New Method Diagnoses Deadly Fungal Lung Infection
By LabMedica International staff writers Posted on 29 Dec 2015 |
![Image: The AB Sciex 5800 MALDI TOF/TOF mass spectrometer (Photo courtesy of Sciex). Image: The AB Sciex 5800 MALDI TOF/TOF mass spectrometer (Photo courtesy of Sciex).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-12-29/RLJ-426a.jpg)
Image: The AB Sciex 5800 MALDI TOF/TOF mass spectrometer (Photo courtesy of Sciex).
A new way has been discovered for the early detection of a potentially deadly fungal infection in patients with suppressed immune systems such as those being treated for leukemia or have had an organ transplant.
Patients receiving leukemia chemotherapy treatments, bone marrow stem cell transplants or lung transplants are some of those at risk for serious infection by the disease-causing Aspergillus fungus, a common mold in the environment that easily becomes airborne. When inhaled, the mold colonizes the respiratory tract and in patients with immune suppression from their chemotherapy treatment, the mold invades into the bloodstream where it spreads and infects several organs including the liver, lungs and brain.
A multidisciplinary team led by scientists at The University of Texas Medical Branch (Galveston, TX, USA) enrolled patients undergoing chemotherapy, stem cell transplantation and lung transplantation in a multisite prospective observational trial. Proven and probable invasive pulmonary aspergillosis (IPA) cases and matched controls were subjected to discovery proteomics analyses using a biofluid analysis platform, fractionating plasma into reproducible protein and peptide pools.
Of the 61 IPA cases, serum galactomannan (GM) was assayed in 60, of which 36 tests were positive. Bronchoalveolar lavage GM was assayed in 35 cases of which 30 were positive. A positive serum GM was the only mycological criteria in 22 of the 61 cases. Independent testing of GM was performed on all IPA cases using serum collected on the same day as samples used for proteomics analysis. Those who developed probable or proven IPA where selected for subsequent proteomics studies.
For the 2D gel electrophoresis (2DE) spots that were significantly differentially expressed were picked robotically, trypsin-digested, and peptides identified by MALDI TOF/TOF (AB Sciex 5800; Foster City, CA, USA). Plasma concentrations of interleukin (IL)-6, -10, tumor necrosis factor (TNF)-α, plasminogen activator inhibitor (PAI)-1, Factor VIII, and Von Willebrand factor (vWF) were assayed by sandwich ELISA (Bioplex; Bio-Rad, Hercules, CA, USA). The Platelia Aspergillus enzyme immunoassay (EIA) (Bio-Rad Laboratories; Redmond, WA, USA;) was also performed.
From 556 spots identified by 2D gel electrophoresis, 66 differentially expressed post-translationally modified plasma proteins were identified in the leukemic subgroup only. This protein group was rich in complement components, acute-phase reactants and coagulation factors. Low molecular weight peptides corresponding to abundant plasma proteins were identified. A candidate marker panel of host response (nine plasma proteins, four peptides), fungal polysaccharides (galactomannan), and cell wall components (β-D glucan, BG) were selected by statistical filtering for patients with leukemia as a primary underlying diagnosis. The test results for the mold were different for each group of patients, so future commercial diagnostic tests using this technology should be tailored for different medical conditions commonly linked with this infection.
The authors concluded that they had confirmed, and evaluated a multicomponent predictive panel for the presence of IPA in a prospective cohort of immunocompromised patients in a multicenter registry. Two important findings are that host response proteins contribute independent information to that of GM or BG, and that diagnostic host response proteins of IPA are significantly influenced by the primary underlying disease. The study was published on November 18, 2015, in the journal Public Library of Science ONE.
Related Links:
The University of Texas Medical Branch
AB Sciex
Bio-Rad
Patients receiving leukemia chemotherapy treatments, bone marrow stem cell transplants or lung transplants are some of those at risk for serious infection by the disease-causing Aspergillus fungus, a common mold in the environment that easily becomes airborne. When inhaled, the mold colonizes the respiratory tract and in patients with immune suppression from their chemotherapy treatment, the mold invades into the bloodstream where it spreads and infects several organs including the liver, lungs and brain.
A multidisciplinary team led by scientists at The University of Texas Medical Branch (Galveston, TX, USA) enrolled patients undergoing chemotherapy, stem cell transplantation and lung transplantation in a multisite prospective observational trial. Proven and probable invasive pulmonary aspergillosis (IPA) cases and matched controls were subjected to discovery proteomics analyses using a biofluid analysis platform, fractionating plasma into reproducible protein and peptide pools.
Of the 61 IPA cases, serum galactomannan (GM) was assayed in 60, of which 36 tests were positive. Bronchoalveolar lavage GM was assayed in 35 cases of which 30 were positive. A positive serum GM was the only mycological criteria in 22 of the 61 cases. Independent testing of GM was performed on all IPA cases using serum collected on the same day as samples used for proteomics analysis. Those who developed probable or proven IPA where selected for subsequent proteomics studies.
For the 2D gel electrophoresis (2DE) spots that were significantly differentially expressed were picked robotically, trypsin-digested, and peptides identified by MALDI TOF/TOF (AB Sciex 5800; Foster City, CA, USA). Plasma concentrations of interleukin (IL)-6, -10, tumor necrosis factor (TNF)-α, plasminogen activator inhibitor (PAI)-1, Factor VIII, and Von Willebrand factor (vWF) were assayed by sandwich ELISA (Bioplex; Bio-Rad, Hercules, CA, USA). The Platelia Aspergillus enzyme immunoassay (EIA) (Bio-Rad Laboratories; Redmond, WA, USA;) was also performed.
From 556 spots identified by 2D gel electrophoresis, 66 differentially expressed post-translationally modified plasma proteins were identified in the leukemic subgroup only. This protein group was rich in complement components, acute-phase reactants and coagulation factors. Low molecular weight peptides corresponding to abundant plasma proteins were identified. A candidate marker panel of host response (nine plasma proteins, four peptides), fungal polysaccharides (galactomannan), and cell wall components (β-D glucan, BG) were selected by statistical filtering for patients with leukemia as a primary underlying diagnosis. The test results for the mold were different for each group of patients, so future commercial diagnostic tests using this technology should be tailored for different medical conditions commonly linked with this infection.
The authors concluded that they had confirmed, and evaluated a multicomponent predictive panel for the presence of IPA in a prospective cohort of immunocompromised patients in a multicenter registry. Two important findings are that host response proteins contribute independent information to that of GM or BG, and that diagnostic host response proteins of IPA are significantly influenced by the primary underlying disease. The study was published on November 18, 2015, in the journal Public Library of Science ONE.
Related Links:
The University of Texas Medical Branch
AB Sciex
Bio-Rad
Latest Microbiology News
- POC STI Test Shortens Time from ED Arrival to Test Results
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
Channels
Molecular Diagnostics
view channel![Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics) Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-14/2024_Doctor-Holding-Kit.jpg)
Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more![Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche) Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-13/image-media-info-cobas-liat-system-tube.jpg)
Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more![Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock) Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-12/AdobeStock_480745598 (1).jpeg)
First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance... Read more![Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding) Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-11/proteomics-and-transcriptomics-1000x563.jpg)
Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood... Read moreHematology
view channel![Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia) Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/C3_DBS_Website.2.jpg)
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more![Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols) Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-08/donor-testing-1.jpg)
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more![Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health) Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-20/news-7.jpg)
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more![Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health) Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-02-08/inserting-hb-variant-cartridge.jpg)
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel![Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute) Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/Surgical oncology 43 (1).jpg)
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more![Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer) Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-03/906uv0fs34hr.jpg)
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read moreMicrobiology
view channel![Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical) Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/device-front.jpg)
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more![Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock) Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-08/shutterstock_1065839396.jpg)
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more![Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB) Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-07/ASTar_ft-1-700x494.jpg)
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more![Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche) Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-02/cobas-eplex-in-copy-image_2.jpg)
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read morePathology
view channel![Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock) Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-14/shutterstock_447424987.jpg)
New Technique Reveals Earliest Signs of Genetic Mutations
Mutations are alterations in the molecular "letters" that constitute the DNA code, which serves as the blueprint for all living cells. While some of these changes may be inconsequential, others can lead... Read more![Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová) Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-13/Low-Res_jctp-23-68-g005.jpg)
New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
Lung cancer continues to be the most common cause of cancer-related deaths worldwide and ranks as the second most frequently diagnosed cancer in both men and women. The role of lung cytopathology, which... Read more![Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine) Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-12/inline_Untitled-3.jpg)
Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.... Read more![Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF) Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-11/17907939_m_normal_none_1.jpg)
Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
Scientists at Brown University (Providence, RI, USA) and the University of Michigan (Ann Arbor, MI, USA) have created a groundbreaking computational technique to examine complex tissue data, potentially... Read moreTechnology
view channel![Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet) Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/plaster_custom20240529112158.jpg)
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more![Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz) Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/new-diagnostic-tool-ac.jpg)
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read moreIndustry
view channel![Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche) Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-28/download.jpg)
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more![Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF) Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-13/103048801_m_normal_none.jpg)
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more![Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter) Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-09/PR_partnership_with_Beckman_Coulter_v1_2.jpg)
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more![Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF) Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-01/130140677_m_normal_none (1)_1.jpg)